DGX Stock Overview
Provides diagnostic testing and services in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
My Notes
Capture your thoughts, links and company narrative
Quest Diagnostics Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$164.17 |
| 52 Week High | US$165.32 |
| 52 Week Low | US$123.04 |
| Beta | 0.90 |
| 1 Month Change | 8.82% |
| 3 Month Change | 5.72% |
| 1 Year Change | 29.09% |
| 3 Year Change | 20.44% |
| 5 Year Change | 46.99% |
| Change since IPO | 4,590.57% |
Recent News & Updates
Quest Diagnostics: Good Growth Prospects, But Little To No Upside Left At Current Valuation
Jan 28Quest Diagnostics Incorporated (NYSE:DGX) Could Be Riskier Than It Looks
Jan 26
Recent updates
Quest Diagnostics: Good Growth Prospects, But Little To No Upside Left At Current Valuation
Jan 28Quest Diagnostics Incorporated (NYSE:DGX) Could Be Riskier Than It Looks
Jan 26Is Quest Diagnostics (NYSE:DGX) A Risky Investment?
Dec 18Is Now The Time To Look At Buying Quest Diagnostics Incorporated (NYSE:DGX)?
Nov 30Investors Met With Slowing Returns on Capital At Quest Diagnostics (NYSE:DGX)
Nov 12Earnings Update: Quest Diagnostics Incorporated (NYSE:DGX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Oct 25Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat
Oct 24Why Investors Shouldn't Be Surprised By Quest Diagnostics Incorporated's (NYSE:DGX) P/E
Oct 23Quest Diagnostics: The Better Half Of An Emerging Healthcare Duopoly
Oct 15These 4 Measures Indicate That Quest Diagnostics (NYSE:DGX) Is Using Debt Reasonably Well
Aug 30Should You Think About Buying Quest Diagnostics Incorporated (NYSE:DGX) Now?
Aug 12Quest Diagnostics: Beat Down After Beating Q2 Estimates
Jul 28The Price Is Right For Quest Diagnostics Incorporated (NYSE:DGX)
Jul 12Quest Diagnostics: On A Quest For Growth
Jul 12Quest Diagnostics (NYSE:DGX) Hasn't Managed To Accelerate Its Returns
May 14Quest Diagnostics: Let's Keep Waiting
May 08Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts
Apr 26We Think Quest Diagnostics (NYSE:DGX) Can Stay On Top Of Its Debt
Apr 23Unpleasant Surprises Could Be In Store For Quest Diagnostics Incorporated's (NYSE:DGX) Shares
Apr 02Quest Diagnostics (NYSE:DGX) Is Paying Out A Larger Dividend Than Last Year
Mar 15Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.75
Feb 06Quest Diagnostics: Post-COVID Normalization Pretty Much Done
Feb 05Quest Diagnostics: Market Overreaction Creates Investment Opportunity
Dec 08Quest Diagnostics: Moving Past Covid
Oct 25Quest Diagnostics: Q2 Earnings Reveal Promising Growth Trends Despite Dwindling COVID Testing Revenues
Aug 15Shareholder Returns
| DGX | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 8.1% | 3.5% | -0.8% |
| 1Y | 29.1% | -0.07% | 25.2% |
Return vs Industry: DGX exceeded the US Healthcare industry which returned -0.1% over the past year.
Return vs Market: DGX exceeded the US Market which returned 25.2% over the past year.
Price Volatility
| DGX volatility | |
|---|---|
| DGX Average Weekly Movement | 2.5% |
| Healthcare Industry Average Movement | 8.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.7% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: DGX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: DGX's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1967 | 44,000 | Jim Davis | www.questdiagnostics.com |
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals.
Quest Diagnostics Incorporated Fundamentals Summary
| DGX fundamental statistics | |
|---|---|
| Market cap | US$17.35b |
| Earnings (TTM) | US$871.00m |
| Revenue (TTM) | US$9.87b |
21.0x
P/E Ratio1.9x
P/S RatioIs DGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DGX income statement (TTM) | |
|---|---|
| Revenue | US$9.87b |
| Cost of Revenue | US$6.63b |
| Gross Profit | US$3.24b |
| Other Expenses | US$2.37b |
| Earnings | US$871.00m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.80 |
| Gross Margin | 32.86% |
| Net Profit Margin | 8.82% |
| Debt/Equity Ratio | 81.4% |
How did DGX perform over the long term?
See historical performance and comparisonDividends
1.8%
Current Dividend Yield39%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 23:28 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Quest Diagnostics Incorporated is covered by 47 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Brian Kemp Dolliver | Avondale Partners |
| Eric Coldwell | Baird |